<DOC>
	<DOCNO>NCT01377012</DOCNO>
	<brief_summary>The core extension study assess safety efficacy secukinumab add background therapy patient active rheumatoid arthritis intolerant inadequate response anti-TNF-α agent . Patients receive either secukinumab , placebo . The core study complete . However , extension study terminate early ( unrelated safety ) due result study AIN457F2309 , indicate efficacy AIN457 comparable currently available RA treatment , abatacept , thus lead close AIN457 RA program .</brief_summary>
	<brief_title>Efficacy 24 Weeks Safety , Tolerability Long Term Efficacy 2 Years Secukinumab ( AIN457 ) Patients With Active Rheumatoid Arthritis Inadequate Response Anti-TNFα Agents</brief_title>
	<detailed_description>CAIN457F2302 ( Core Study ) : Completed Sep 9 2015 CAIN457F2302E1 ( Extension study ) : terminate early May 26 2015 , ( ( unrelated safety ) due result study AIN457F2309 , indicate efficacy AIN457 comparable currently available RA treatment , abatacept , thus lead close AIN457 RA program .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Male nonpregnant , nonlactating female patient Presence RA classify American College Rheumatology ( ACR ) 2010 revise criterion least 3 month screen At Baseline : Disease activity criterion define ≥ 6 tender joint 68 ≥6 swollen joint 66 least 1 follow screening : AntiCyclic Citrullinated Peptide ( CCP ) antibodies positive OR Rheumatoid Factor positive least 1 follow screening : High sensitivity Creactive protein ( hsCRP ) ≥ 10 mg/L OR Erythrocyte sedimentation rate ( ESR ) ≥ 28 mm/1st hr Patients must take least one antiTNFα agent give approve dose least 3 month randomization experience inadequate response treatment intolerant least one administration antiTNFα agent Patients must take MTX least 3 month randomization stable dose least 4 week randomization ( 7.5 25 mg/week For Japan : 6 25 mg/week ) Exclusion criterion : Chest xray evidence ongoing infectious malignant process , obtain within 3 month prior screen evaluate qualified physician RA patient functional status class IV accord ACR 1991 revise criterion Patients ever receive biologic immunomodulating agent except target TNFα Previous treatment celldepleting therapy include limited antiCD20 , investigational agent ( e.g. , CAMPATH , antiCD4 , antiCD5 , antiCD3 , antiCD19 ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>ACR</keyword>
	<keyword>inflammatory joint</keyword>
</DOC>